[go: up one dir, main page]

WO2008088594A3 - Isolation of antibodies that cross-react and neutralize rankl orginating from multiple species - Google Patents

Isolation of antibodies that cross-react and neutralize rankl orginating from multiple species Download PDF

Info

Publication number
WO2008088594A3
WO2008088594A3 PCT/US2007/079938 US2007079938W WO2008088594A3 WO 2008088594 A3 WO2008088594 A3 WO 2008088594A3 US 2007079938 W US2007079938 W US 2007079938W WO 2008088594 A3 WO2008088594 A3 WO 2008088594A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
binding members
rankl
specific binding
cross
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/079938
Other languages
French (fr)
Other versions
WO2008088594A2 (en
Inventor
William J Boyle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ANAPTYS BIOSCIENCES Inc
Original Assignee
ANAPTYS BIOSCIENCES Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ANAPTYS BIOSCIENCES Inc filed Critical ANAPTYS BIOSCIENCES Inc
Publication of WO2008088594A2 publication Critical patent/WO2008088594A2/en
Publication of WO2008088594A3 publication Critical patent/WO2008088594A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides specific binding members (e g, antibodies or antigen-binding fragments thereof) which bind to RANKL originating from multiple species. An epitope recognized by the specific binding members can be selected from surface exposed loop domains that bind to and activate its cognate receptor, RANK (Receptor Activator of NFkB), on the surface of osteoclast precursors and other cell types. The invention provides peptides for generating such anti-RANKL antibodies, including murine sequences, other non-human sequences and cross- reactive peptides. The specific binding members are useful m the diagnosis and treatment of lytic bone diseases, including osteoporosis, rheumatoid arthritis, bone metastasis and hypercalcemia of malignancy, glucocorticoid- mduced bone loss, a periodontal disease or condition, a cancer and Juvenile Paget's Disease. The binding members can also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or antigen-bmding fragments thereof.
PCT/US2007/079938 2007-01-12 2007-09-28 Isolation of antibodies that cross-react and neutralize rankl orginating from multiple species Ceased WO2008088594A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62292807A 2007-01-12 2007-01-12
US11/622,928 2007-01-12

Publications (2)

Publication Number Publication Date
WO2008088594A2 WO2008088594A2 (en) 2008-07-24
WO2008088594A3 true WO2008088594A3 (en) 2008-10-30

Family

ID=39638822

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/079938 Ceased WO2008088594A2 (en) 2007-01-12 2007-09-28 Isolation of antibodies that cross-react and neutralize rankl orginating from multiple species

Country Status (1)

Country Link
WO (1) WO2008088594A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2009001735A1 (en) 2008-08-19 2010-02-19 Regeneron Pharma Human antibody or antigen-binding fragment thereof that binds and inhibits ligand activity of the nf-kb receptor activator (rankl); encoding dna; expression vector; method of producing said antibody; pharmaceutical composition comprising it; use to attenuate or inhibit rankl-mediated disease or condition
WO2011017294A1 (en) * 2009-08-07 2011-02-10 Schering Corporation Human anti-rankl antibodies
JPWO2012133914A1 (en) * 2011-03-31 2014-07-28 オリエンタル酵母工業株式会社 Cancer immunity enhancer containing RANKL antagonist
HK1216754A1 (en) * 2013-03-14 2016-12-02 Apexigen, Inc. Anti-rankl antibodies and methods of use
WO2015018421A1 (en) 2013-08-07 2015-02-12 Rigshospitalet Copenhagen University Hospital Antibodies, compounds and derivatives thereof for use in the treatment of male infertility
BR112019006127A2 (en) * 2016-10-28 2019-06-18 Lilly Co Eli anti-rankl antibodies and uses of these

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US6645500B1 (en) * 1998-09-15 2003-11-11 M & E Biotech A/S Method for down-regulating osteoprotegerin ligand activity
US20040097712A1 (en) * 2002-09-06 2004-05-20 Amgen, Inc. A Corporation Of The State Of Delaware Therapeutic human anti-IL1-R1 monoclonal antibody
US20060069098A1 (en) * 2003-12-25 2006-03-30 Shiro Miyoshi Bicyclic compound
US7128911B2 (en) * 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US6645500B1 (en) * 1998-09-15 2003-11-11 M & E Biotech A/S Method for down-regulating osteoprotegerin ligand activity
US7128911B2 (en) * 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US20040097712A1 (en) * 2002-09-06 2004-05-20 Amgen, Inc. A Corporation Of The State Of Delaware Therapeutic human anti-IL1-R1 monoclonal antibody
US20060069098A1 (en) * 2003-12-25 2006-03-30 Shiro Miyoshi Bicyclic compound

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TANAKA ET AL.: "Role of RANKL in physiological and pathological bone resorption and therapeutics targeting in RANKL-RANK signaling system", IMMUNOL. REVIEWS, vol. 208, 2005, pages 30 - 49 *

Also Published As

Publication number Publication date
WO2008088594A2 (en) 2008-07-24

Similar Documents

Publication Publication Date Title
LTPA2022520I1 (en)
NZ773507A (en) Chimeric antigen receptor
WO2008088594A3 (en) Isolation of antibodies that cross-react and neutralize rankl orginating from multiple species
MY160892A (en) Antibodies to ccr2
UA104587C2 (en) Monoclonal antibody and a method of use thereof
NZ601617A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
MX2009002571A (en) Anti-activin a antibodies and uses thereof.
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
JOP20190017A1 (en) Human cgrp receptor binding antibodies
UA106036C2 (en) Normal;heading 1;heading 2;heading 3;ANTI-MESOTHELIN ANTIBODY AND USES THEREOF
MX2007006921A (en) Compositions and methods relating to anti igf-1 receptor antibodies.
MY187263A (en) Il-17 reception a antigen binding proteins
WO2003034903A3 (en) Psma antibodies and protein multimers
BRPI0715017A8 (en) glucagon receptor antibody compositions and methods
SG196697A1 (en) Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
PH12015502479B1 (en) Cd19 specific chimeric antigen receptor and uses thereof
GEP20125612B (en) Prlr-specific antibody and usage thereof
CL2009000586A1 (en) Humanized monoclonal antibody or fab fragment comprising it that binds human glucagon / glucr, rat, mouse, and monkey cynomolgus receptor; vector comprising coding polynuccleotide; host cell that understands it; pharmaceutical composition; use to treat type 1 or 2 diabetes, or for weight loss
JP2013506428A5 (en)
EA201270769A1 (en) ANTIBODIES TO CGRP
MX2011008971A (en) ANTI-CεmX ANTIBODIES CAPABLE OF BINDING TO HUMAN mIgE ON B LYMPHOCYTES.
SA521430654B1 (en) Rituximab-resistant chimeric antigen receptors and their uses
DK1711531T3 (en) Neutralizing anti-TLR4 / -MD-2 antibodies and methods for their use
MX2025008002A (en) Cd19-specific antibody constructs and compositions thereof
MX2009008754A (en) Novel antibodies against igf-ir.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07843512

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07843512

Country of ref document: EP

Kind code of ref document: A2